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ABSTRACT
Objective: To estimate the impact of medication adherence on the cost–
effectiveness of mass-screening by bone densitometry followed by alend-
ronate therapy for women diagnosed with osteoporosis.
Methods: A validated Markov microsimulation model with a Belgian
health-care payer perspective and a lifetime horizon was used to assess the
cost per quality-adjusted life year (QALY) gained of the screening/
treatment strategy compared with no intervention. Real-world adherence
to alendronate therapy and full adherence over 5 years were both inves-
tigated. The real-world adherence scenario employed adherence data from
published observational studies, and medication adherence was divided
into persistence, compliance, and primary adherence. Uncertainty was
investigated using one-way and probabilistic sensitivity analyses.
Results: At 65 years of age, the costs per QALY gained because of the
screening/treatment strategy versus no intervention are €32,008 and
€16,918 in the real-world adherence and full adherence scenarios, respec-
tively. The equivalent values are €80,836 and €40,462 at the age of 55
years, and they decrease to €10,600 and €1229 at the age of 75 years.
Sensitivity analyses show that the presence of the upfront cost of case
ﬁnding has a substantial role in the impact of medication adherence on
cost–effectiveness.
Conclusion: This study indicates that nonadherence with osteoporosis
medications substantially increases the incremental cost–effectiveness ratio
of osteoporosis screening strategies. All aspects of medication adherence
(i.e., compliance, persistence, and primary adherence) should therefore be
reported and included in pharmacoeconomic analyses, and especially in
the presence of the upfront cost of case ﬁnding (such as screening cost).
Keywords: adherence, compliance, cost–effectiveness, osteoporosis, persis-
tence, screening.
Introduction
Medication nonadherence is a widespread public health problem,
especially in chronic diseases such as osteoporosis. Approxi-
mately 75% of women who initiated osteoporosis drug therapy
were shown to be nonadherent with treatment within 1 year, and
almost 50% discontinued therapy by this time [1]. Poor adher-
ence to drug therapy is associated with adverse outcomes, and
nonadherent patients have a signiﬁcantly greater risk of fractures
[2,3]. Such behavior may have a substantial impact on the cost–
effectiveness of interventions [4,5] and, in particular, for screen-
ing strategies which include the upfront cost of case ﬁnding.
Screening for osteoporosis has been widely recommended for
identifying patients at high risk before any fracture occurs [6].
The cost–effectiveness of screening strategies is of obvious impor-
tance, and many studies have been reported in the literature [7].
These studies have mainly investigated the cost–effectiveness
of bone densitometry combined with therapy [8–10], of pre-
screening strategies for bone densitometry (e.g. quantitative
ultrasound or clinical risk factors) [11,12], and of strategies
assessing absolute fracture risk combining clinical risk factors
with bone densitometry [13–17].
Poor adherence to osteoporosis drug therapy was not rou-
tinely included by these studies despite its potential impact.
Moreover, when adherence was included, a lack of methodologi-
cal rigor and consistency in deﬁnitions reduced the impact of
medication nonadherence. Some studies did provide realistic
assumptions with respect to persistence with drug therapy [8,10],
but additional adherence effects (such as inappropriate use of
drug therapy or primary nonadherence) were largely neglected.
These problems may result in the overestimation of the cost–
effectiveness of osteoporosis screening [8].
In light of these limitations, this study aimed to evaluate the
impact of all aspects of medication nonadherence (i.e., non-
compliance, nonpersistence, and primary nonadherence) on the
cost–effectiveness of osteoporosis screening. Using our validated
Markov microsimulation model, recently published in Value in
Health [18], we estimated the cost per quality-adjusted life year
(QALY) gained of bone densitometry combined with alendronate
therapy for those who have osteoporosis, compared with no
intervention. We also assessed the impact of the upfront cost of
case ﬁnding on the effect of medication adherence on cost–
effectiveness. Bone densitometry is the most widely used and
recommended instrument to establish or conﬁrm a diagnosis of
osteoporosis [6]. Despite the new World Health Organization
paradigm of treating osteoporosis based on absolute fracture risk
rather than bone density alone [19], bone densitometry remains
a vital component in the diagnosis and management of
osteoporosis [20]. In Belgium, the reference country for the
analysis, as in many other European countries, drug therapy is
actually only reimbursed for patients with a bone mineral density
(BMD) t-score  -2.5, deﬁned by bone densitometry, or in the
presence of one or more fragility fracture.
Methods
Deﬁning Adherence
Because a wide variety of deﬁnitions for medication adherence
are used in the literature [4,21], there is a need to deﬁne the
terminology. Recently, the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) Medication
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Compliance and Persistence Workgroup set out deﬁnitions [22].
Medication adherence is a general term encompassing differ-
ent aspects explained below, i.e., persistence, compliance, and
primary adherence.
Medication persistence is deﬁned by ISPOR as “the length of
time from initiation to discontinuation of therapy” [22]. It may
be reported as the proportion of patients still taking medication
at the end of a predeﬁned time period. Medication compliance is
deﬁned as “the extent to which a patient acts in accordance with
the prescribed interval and dose of a dosing of regimen” [22]. It
is often reported as the number of doses taken in relation to the
dispensing period, often called the “medication possession ratio
(MPR)” [22]. Primary nonadherence, frequently mentioned in
the literature [6,23], is assumed for patients diagnosed with
osteoporosis but who did not take any medication.
Screening/Treatment Strategy
A decision analytic model was used to compare the screening/
treatment strategy with no intervention (Fig. 1). The screening/
treatment strategy consisted of bone densitometry combined
with a 5-year alendronate therapy for women diagnosed with
osteoporosis (BMD T-score  -2.5) and who are primary adher-
ent. Prevalence of osteoporosis was derived from the recom-
mended National Health and Nutrition Examination Survey
(NHANES) III [24] reference database and the proportions of
women diagnosed as having osteoporosis were therefore 6.95%,
15.07%, and 28.96%, respectively for those aged 55, 65, and 75
years. The cost of bone densitometry measurement was estimated
at €47 per patient (in 2006) and included the dual-energy x-ray
absorptiometry cost (€27) and one physician visit (€20) [11].
Economic Model
A Markov microsimulation model using decision analysis soft-
ware (TreeAgePro 2006 Suite, release 0.4, TreeAge Software,
Inc., Williamstown, MA) was used to estimate the cost–
effectiveness of the screening/treatment strategy compared with
no intervention. The model development and validation was
recently published in Value in Health [18]; and the model was
previously used to estimate the effects of changes in baseline
population risk and changes in life expectancy on absolute life-
time fracture risks [25].
The model health states were no fracture, death, hip fracture,
clinical vertebral fracture, forearm fracture, and other fracture.
The cycle length of the model was 1 year and the model followed
the patients individually until they died or reached the age of 105
years. The required time horizon to fully evaluate the beneﬁt of
a particular intervention should be very long because fractures
have long-term impact on quality of life and are associated with
long-term costs. The use of a lifetime horizon has therefore been
recommended for health economic analyses conducted in
osteoporosis [26]. The patient history was recorded by so-called
“tracker” variables and thus, prior fractures and current residen-
tial status (either in the community or in a nursing home) were
used in calculations of transition probabilities, effectiveness, and
costs. All the women began in the state “no fracture” and all the
transitions between health states were possible in each cycle and
regardless of the current state. Each state has its associated costs
and effectiveness, depending on the patient history.
The current study was performed from a health-care payer
perspective including direct health-care costs paid by the com-
pulsory national health insurance and the patient’s out-of-pocket
contribution, in line with the Belgian methodological guide-
lines for pharmacoeconomic evaluations [27]. Transition cost
included direct fracture costs in the year following the fracture
and long-term cost beyond the ﬁrst year for women entering a
nursing home after a hip fracture. An adjustment was made to
take into account that women might be institutionalized later in
life in any case, regardless of their hip fracture [18]. Effectiveness
was expressed in QALYs, which is an attractive outcome mea-
surement in the ﬁeld of osteoporosis because it offers the advan-
tage of capturing the beneﬁts from reductions in both morbidity
and mortality [28]. The disutility associated with fractures was
modeled as a relative reduction in QALY [29]. In accordance
with Belgian methodological guidelines for pharmacoeconomic
evaluations [27], discount rates of 3% and 1.5% were assumed
for cost (expressed in 2006) and effectiveness, respectively. For a
detailed description and explanation of the model and data,
please refer to the published paper [18].
Fracture Risk
In the base-case analysis, we investigated women without prior
fracture. In order to accurately reﬂect the fracture risk of women
with osteoporosis (i.e., BMD T-score  -2.5), the estimated inci-
dence rates of ﬁrst fracture in Belgium [25] were adjusted using
a previously described and validated method [30]. This method
calculates the relative risk of individuals below the threshold
value compared with that of the general population.
The number of standard deviations of BMD below the age-
matched average BMD was derived from the recommended
NHANES III [24] database, in which young adult bone mineral
density values were not signiﬁcantly different from Belgian esti-
mates [31]. One standard deviation decrease in BMD was asso-
ciated with an increase in age-adjusted relative risk of 1.8, 1.4,
and 1.6 for clinical vertebral, forearm, and other osteoporotic
fractures, respectively [32]. The relative risk for hip fracture was
shown to decrease with age and ranged from 3.68 at 50 years, to
1.93 at 85 years [33].
Alendronate Therapy
We assumed that treated women received a 5-year alendronate
therapy, the most widely prescribed osteoporosis treatment,
Alendronate therapy
Q
No drug therapy
1-Q
Osteoporosis
P
No drug therapyNo Osteoporosis
1-P
Bone densitometry
No drug therapyOsteoporosis
P
No drug therapyNo Osteoporosis
1-P
No intervention
CEA
Figure 1 Model structure. p represents the preva-
lence of osteoporosis and q the rate of primary
adherence. CEA, Cost–effectiveness analysis.
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worldwide. The clinical effectiveness of alendronate in the treat-
ment of women with osteoporosis has been extensively docu-
mented. A recent meta-analysis was conducted for the National
Institute forHealth andClinical Excellence appraisal and included
large randomized controlled trials and therefore women aged
between 55 years to 81 years at baseline with severe osteoporosis,
osteoporosis, and osteopenia [34]. The relative risks versus
placebo were 0.62 (95% CI 0.40–0.96) for hip fracture, 0.55
(95% CI 0.40–0.66) for clinical vertebral fracture, 0.85 (95%
conﬁdence interval [CI] 0.67–1.09) for forearm fracture, and 0.83
(95% CI 0.74–0.93) for other fracture. These relative risks were
selected for all age groups and the effect of treatment was assumed
to persist for a duration (i.e., offset-time) equal to the duration of
therapy, in line with clinical studies [35,36] and assumptions used
in previous models [9,37,38]. The risk reduction was assumed to
decline linearly to zero during this period.
The cost of treatment included drug costs and costs of assess-
ment. The annual cost of alendronate therapy was estimated at
€308.3 (Fosamax [Merck & Co., Whitehouse Station, NJ],
€70.94 for a package of 12, 70-mg tablets, once per week [39]).
Most of the women treated with alendronate therapy received
calcium and vitamin D supplementation [40,41]. We therefore
included the cost of calcium and vitamin D (Steovit D3
[Nycomed, Brussels, Belgium], 500 mg calcium and 400 IU
vitamin D, €14.99 for 60 tablets, once per day [42]). In accor-
dance with previous standard assumptions regarding the moni-
toring of osteoporotic treatments [28], we assumed that
treatment was associated with one yearly general practitioner’s
visit (€20) and one bone densitometry measurement every second
year (estimated at €47) [11]. No adverse events were assumed in
the base-case analysis, because the overall safety proﬁle of alen-
dronate is favorable [6].
Adherence Data
Clinical effectiveness and drug costs are affected by poor compli-
ance and failure to persist with therapy. Adherence to alendronate
therapy (daily and weekly combined) in real-life setting was
derived from a recent published Belgian study [2], the reference
country for the analysis. For modeling purposes, adherence was
divided into primary adherence, persistence, and compliance.
First, primary nonadherence was estimated at 11.6% in a
published Belgian study [43]. This study showed that only 88.4%
of women initiated any medication after a diagnosis of
osteoporosis. Primary nonadherent patients were assumed to
only incur the cost of screening.
Then, 42.5% of those who initiated treatment discontinued it
within 6 months [2]. For these women, no treatment effect was
assumed, and we assigned 3 months of therapy cost, as previ-
ously suggested [23]. Another 18.1%, 13.9%, and 7.2% of
women dropped off therapy at 1-year, 2-year, and 3-year, respec-
tively. Therefore, only 18.2% of the women received a 5-year
treatment. It was assumed that if patients discontinue therapy,
they received no further treatment and offset-time for non-
persistent patients was the same as the duration on therapy.
Finally, women taking medication were considered to be com-
pliant if their MPR was at least 80% in any given year and poorly
compliant otherwise. An MPR  80% was most commonly used
to deﬁne high compliance [44]. The probabilities of being less
than 80% compliant were estimated at 23.9%, 4.0%, and 1.2%
in the ﬁrst, second, and following years of treatment, respectively
[2]. These women beneﬁt from a lower treatment efﬁcacy. Poor
compliance (MPR < 80%) was associated with a 35% increase in
hip fracture rate (relative risk [RR] = 1.35, 95% CI 1.17–1.56) in
line with the Belgian study [2]. Because this study did not assess
the relationship between compliance and non–hip fractures, we
assumed a conservative [44] 17% increase in other fractures rates
(RR = 1.17, 95% CI 1.09–1.25) [45], for poorly compliant
women. The relative risks from the systematic review were appli-
cable to the population with a compliance of 80% or greater. So,
for example, if alendronate was assumed to reduce the risk of hip
fracture by 38%, then compliant women would experience a
38% reduction in hip fractures while noncompliant women
would experience only a 16% (0.62 ¥ 1.35 = 0.837) reduction in
hip fractures. For poorly compliant women, drug cost was
reduced by 20%.
Because adherence rates differ between jurisdictions
[44,46,47], additional analyses were conducted assuming that
adherence rates were 20% and 40% higher than in the real-world
scenario. In other terms, the probabilities of being primary non-
adherent and poorly compliant, and the dropout rates in the
real-world setting were reduced by 20% and 40%, respectively.
Presentation of Results and Sensitivity Analyses
For each analysis, the incremental cost–effectiveness ratio (ICER)
was computed as the difference between the screening/treatment
strategy and no intervention in terms of total costs divided by the
difference between them in terms of effectiveness, expressed in
accumulated QALYs. A total of 200,000 ﬁrst-order Monte Carlo
simulations were deemed sufﬁcient to ensure stability of the
results. An ICER represents the cost of the screening/treatment
strategy per one QALY gained, compared with no intervention.
Although the ICER is increasingly used in the decision-making
progress, there is no consensus on the cost per QALY that rep-
resents acceptable value for money. Decision-making process
depends on many elements other than cost–effectiveness, such as
preferences or budget impact. Belgian decision-makers have
therefore not deﬁned threshold values below which an interven-
tion can be considered cost–effective [48].
ICER was estimated for real-world adherence to alendronate
therapy and for full adherence over 5 years (to estimate the
theoretical potential). One-way and probabilistic sensitivity
analyses were performed to investigate the uncertainty related to
assumptions and model parameters on the results of the base-case
analysis. One-way sensitivity analyses assessed the impact of
variations in single parameter and base-case assumption. Dis-
count rates, fracture disutility, fracture cost, fracture risk, therapy
cost, treatment efﬁcacy, and offset time were varied over plausible
ranges. Reductions in nonadherence rates were also tested, as well
as changes in speciﬁc aspects of medication adherence (i.e., com-
pliance, persistence, primary adherence, or the increase in fracture
rates for poorly compliant women). One-way sensitivity analyses
were also conducted assuming the cost of generic alendronate (i.e.,
Beenos [Mithra, Brussels, Belgium], €37.8 for a package of 12,
70-mg tablets, once perweek [39]). Additional variation of screen-
ing cost per patient was assumed to cover changes in the cost of
bone densitometry but also, indirectly, uncertainty around
osteoporosis prevalence rates in the target populations.
Probabilistic sensitivity analyses assessed the effects of uncer-
tainty in all model parameters simultaneously. Lognormal distri-
butions were assumed for the relative fracture risks of women
with osteoporosis, of alendronate therapy and of noncompliant
women, as recommended by Briggs’s book for relative risk
parameters [49]. A uniform distribution was also assumed for the
cost of screening with a range from 70% to 130% of the base
value. Distributions for other parameters have been published
elsewhere [18]. Cost–effectiveness acceptability curves were then
constructed from the incremental cost and QALYs of the
screening/treatment strategy in comparison with no intervention
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for 150 second-order Monte Carlo simulations. They show the
probability that the screening/treatment strategy is cost–effective
compared with no intervention as a function of the thresholds
willingness to pay per QALY.
Results
The lifetime costs, QALYs, and the ICER for the screening/
treatment strategy versus no intervention are shown in Table 1,
according to age and medication adherence. In the case of real-
world adherence, the QALY gains of the screening/treatment
strategy compared with no intervention were estimated at
0.0152, 0.0208, and 0.0163 at the ages of 55, 65, and 75 years,
respectively. These values represented only 30.2%, 32.1%, and
34.2% of the one estimated with full adherence assumption. The
cost per QALY gained for the screening/treatment strategy was
shown to progressively decrease with increasing age of screening
and to be highly sensitive to medication adherence. At the ages of
55 and 65 years, the ICERs of the screening/treatment strategy
were approximately doubled under real-world adherence when
compared with full adherence.
Assuming a 20% increase in adherence rates reduced the cost
per QALY gained of the screening/treatment strategy at €63,482,
€25,416, and €6379 at the ages of 55, 65, and 75 years, respec-
tively (Fig. 2). The equivalent values decreased to €54,000,
€22,723, and €4258 when assuming an increase of 40%. If we
assumed the cost of generic alendronate, the ICER of the
screening/treatment strategy at 65 years of age was €20,055 and
€6322 in the real-world adherence and full adherence scenarios,
respectively (Fig. 3). The equivalent values were €65,236 and
€28,505 at the age of 55 years, and the screening/treatment
strategy was cost-saving (i.e., lower cost and higher effectiveness)
at the age of 75 years, even in the case of real-world adherence.
The impact of additional one-way sensitivity analyses on the
ICER were conducted at the age of 65 years (Table 2). Each
aspect of medication adherence was speciﬁcally assessed. The
ICER was markedly reduced when assuming full persistence and
no changes in compliance and primary nonadherence rates; while
the cost–effectiveness was less sensitive to changes in compliance
or in primary adherence. The increase in fracture rates for poorly
compliant women had a limited impact on the results. Other
one-way sensitivity analyses showed moderate increases in the
cost per QALY gained with assumed lower fracture disutility,
lower fracture costs and more marked increases with higher
discount rates, lower fracture risk, higher therapy cost, and lower
treatment efﬁcacy (Table 2). Although model parameters and
treatment speciﬁcities had an impact on the ICER of the
screening/treatment strategy, they did not signiﬁcantly inﬂuence
the relative difference between real-world and full adherence.
Screening cost had a large impact on the effect of medication
adherence on the ICER of the screening/treatment strategy
(Fig. 4). At the screening age of 65 years, the ratio between
real-world and full adherence, estimated at 1.89 (= 32,008/
16,918), in the base-case analysis, decreased to 1.62 if screening
cost was reduced by 50% and increased to 2.09 for a 50%
increase of screening cost. When assuming no upfront ﬁxed cost
of case-ﬁnding, the ratio decreased to 1.35.
The probability that the screening/treatment strategy was
cost-effective compared with no intervention increased with
increasing age of screening and with improving medication adher-
ence (Fig. 5). At a willingness to pay of €40,000, the screening/
treatment strategy had a probability of being cost–effective
respectively of 79.3%, 59.3%, and 2.7%at the ages of 75, 65, and
55 years in the case of real-world adherence. The equivalent
probabilities were 88.7%, 90.7%, and 40.7% under full adher-
ence assumption. The probabilities that the screening/treatment
strategy was cost-saving were 15.3% and 42.7% at the age of 75
years, respectively, in the case of real-world and full adherence.
Discussion
Medication nonadherence has important negative consequences
for clinical outcomes as well as for cost–effectiveness, and, in
Table 1 Lifetime costs,QALYs, and ICER (cost in € per QALY gained) of
the screening/treatment strategy versus no intervention, according to
screening age and medication adherence
No
intervention
Screening/treatment strategy
Real-world
adherence
Full
adherence
Aged 55 years
Costs (€) 10,288.0 11,515.0 12,326.4
QALYs 18.0509 18.0661 18.1013
ICER, €/QALY 80,836 40,462
Aged 65 years
Costs (€) 11,561.6 12,227.4 12,656.2
QALYs 12.9312 12.9520 12.9959
ICER, €/QALY 32,008 16,918
Aged 75 years
Costs (€) 11,120.0 11,291.7 11,178.3
QALYs 8.0289 8.0451 8.0763
ICER, €/QALY 10,600 1,229
ICER, incremental cost–effectiveness ratio; QALY, quality-adjusted life year.
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Figure 2 Impact of medication adherence on the
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particular, for screening strategies which include the upfront cost
of case-ﬁnding. The present study shows that poor adherence
with drug therapy signiﬁcantly reduces the clinical and economic
outcomes of osteoporosis screening strategy. The QALY gain in
the case of real-world adherence represents only 30–35% to that
estimated with full adherence and the cost per QALY gained of
screening strategy versus no intervention was approximately
doubled when assuming real-world adherence compared with
full adherence. Sensitivity analyses showed that the presence of
the upfront cost of case-ﬁnding has a substantial role on the effect
of medication nonadherence on ICER; hence, making ICER, in
this study, highly sensitive to medication adherence through the
cost of screening.
The impact of medication nonadherence on the cost–
effectiveness of osteoporosis screening strategy was greater than
those reported by prior studies. For example, a Swiss-based study
[8] showed that the ICER of a screening strategy was CHF (Swiss
franc)45,545 and CHF55,533 for women aged 65 years under
full and realistic persistence assumption, respectively. For US men
aged 80 years [10], the cost per QALY gained of bone densito-
metry and treatment strategy was $33,128 and $45,587 with full
and realistic adherence assumption. This is because prior studies
have not taken into account all aspects of medication adherence,
rather than because of unusual medication adherence rates in the
present analysis. Most of the prior studies assumed a signiﬁcant
level of medication nonpersistence [7], but additional adherence
effects (such as imperfect use of drug therapy or primary nonad-
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Figure 3 Incremental cost–effectiveness ratio
(cost in € per QALY gained) of the screening/
treatment strategy versus no intervention, assum-
ing the cost of generic alendronate. QALY, quality-
adjusted ife year.
Table 2 One-way sensitivity analyses of incremental cost-effectiveness
ratio (cost in € per quality-adjusted life-year gained) of the screening/
treatment strategy versus no intervention, for women aged 65 years
Parameter
Real-world
adherence
Full
adherence
Base-case 32,008 16,918
Adherence
Full primary adherence* 30,040 —
Full compliance* 30,542 —
Full persistence* 20,794 —
A 17% increase in fracture rates for
poor compliance*
31,246 —
A 35% increase in fracture rates for
poor compliance*
32,491 —
Model parameters
Discount rates 3% (costs and effects) 38,424 19,308
Discount rates 5% (costs and effects) 54,921 28,771
0.75 times base-case fracture risk 52,014 29,958
1.25 times base-case fracture risk 20,320 8,982
0.75 times base-case fracture disutility 39,529 20,863
1.25 times base-case fracture disutility 25,546 14,672
0.75 times base-case fracture cost 37,042 20,156
1.25 times base-case fracture cost 26,250 11,827
0.75 times base-case therapy cost 22,122 8,317
1.25 times base-case therapy cost 40,375 22,301
0.75 times base-case treatment efﬁcacy 52,838 30,614
1.25 times base-case treatment efﬁcacy 20,589 8,888
0.50 times base-case offset time 41,893 22,165
1.50 times base-case offset time 26,923 10,874
*Other aspects of medication adherence are unchanged.
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Figure 4 Incremental cost–effectiveness ratio
(cost in € per QALY gained) of the screening/
treatment strategy versus no intervention accord-
ing to screening cost, for women aged 65 years.
QALY, quality-adjusted life year.
398 Hiligsmann et al.
herence) were largely neglected. Our study assessed all aspects of
medication adherence (i.e., persistence, compliance, and primary
adherence). Although persistence was shown to have the greater
impact on cost–effectiveness, compliance and primary adherence
have also a substantial impact on ICER and should be reported
and incorporated into health economic analyses.
Improving adherence with osteoporosis medications is there-
fore needed to improve the cost–effectiveness of osteoporosis
screening strategy. However, this is a complex and challenging
issue [50]. No clear trends regarding successful interventions
have been identiﬁed [50] and interventions that improve adher-
ence are rarely cost-free. New formulations and dosages schemes
(i.e., monthly oral medication, or quarterly, twice-yearly or
yearly intravenous infusion) have been recently developed, which
in principle can improve adherence [51]. Less frequent dosing
regimens have been frequently associated with better adherence
[52]. The recent introduction of generic alendronate, by decreas-
ing the ﬁnancial burden placed on the payer, may also contribute
to improve the cost–effectiveness of the screening/treatment strat-
egy, if the clinical efﬁcacy, safety, and adherence of generic alen-
dronate will match those of branded alendronate.
The methodology to incorporate adherence into modeling
was conceptually close to the one suggested by Ström et al. [23],
with some remarkable difference. In modeling compliance,
patients were classiﬁed as compliant (MPR  80%) and poorly
compliant (MPR < 80%). The proportions of these groups were
derived for any given year [2] and poorly compliant patients were
assumed to be associated with an increased risk of fractures
[2,45]. Drug cost was also reduced for the poorly compliant
group.
Our results should be analyzed in the light of these limita-
tions, including assumptions on medication adherence. First,
patients were assumed to be poorly compliant if their MPR was
below 80%. This group will be, by deﬁnition, diverse in their
levels of compliance, which would inﬂuence the effect of therapy
on fracture risk and the cost of therapy. A vast majority of poorly
compliant patients had an MPR between 50% and 80% [2] and
were therefore not divided into smaller intervals. Second, drug
cost was assumed to be 100% and 80% of full price for compli-
ant and poorly compliant women, respectively. However, it is
likely that some patients in both groups will not bear all these
costs. Because the mean MPR was not available in these groups,
we conservatively assumed high drug cost. Third, no further
treatment was assumed for patients who discontinued therapy. A
reﬁll gap period of 5 weeks was used in the observational study
to assess persistence [2], which is among the longest reﬁll gap
periods used in previous studies [44]. However, we cannot
exclude that some patients would return to therapy after this
period. A recent study identiﬁed particular patients who return
from temporary interruptions in therapy [53]. Such patients may
affect the results but are difﬁcult to include in modeling because
the effectiveness of oral bisphosphonates used in an intermittent
regimen is unknown. Finally, differences in methodology and in
patients demographics incorporated in the available studies
resulted in wide variations in reported adherence data [47].
Country-speciﬁc data are therefore required because many deter-
minants affected by local conditions may inﬂuence adherence
rates [54].
Our study was constructed in line with the actual reimburse-
ment of osteoporosis drug therapy in Belgium as well as in many
European countries (i.e., women with a BMD T-score  -2.5 or
in the presence of prior fragility fracture). The screening/
treatment strategy was close to that recently reported by Schwen-
kglenks et al. [8] and Schousboe et al. [9]. Our results were
entirely consistent with these studies and with the recommenda-
tions of the National Osteoporosis Foundation recommending
the prescription of bone densitometry in all women over age 65
[20].
Potential limitations may, however, be related to the study
design. First, the prevalence of osteoporosis in the target popu-
lation (i.e., women without fracture) was assumed to be the same
than in the general women population. However, particularly in
those aged 75, a substantial proportion of women with early-
onset osteoporosis will already have fractured or will be treated,
and the remaining population may differ with respect to
osteoporosis prevalence. Although the impact may not be huge,
it will be higher at an older age and the cost–effectiveness differ-
ences between screening ages may be overestimated. Second,
treatment length was restricted to a 5-year period, corresponding
to the duration of most clinical trials. Effectiveness and adher-
ence over a longer period is uncertain and should be assessed in
clinical trials. Finally, many other screening programs are cur-
rently available. Among those, the new World Health Organiza-
tion algorithm (FRAX) recommends to guide treatment decision
based on absolute fracture risk combined bone densitometry
with clinical risk factors, rather than bone density alone [19]. In
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Figure 5 Cost–effectiveness acceptability curves of the screening/treatment strategy versus no intervention, according to age and medication adherence.
RW, real-world; QALY, quality-adjusted life year.
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the context of this paradigm, bone densitometry may have a
more restricted role, but is nonetheless likely to be important for
some subsets of the population [7] and remains a vital compo-
nent in the diagnosis and management of osteoporosis [20].
Further cost–effectiveness modeling studies will be useful in
deﬁning the most cost–effective way bone densitometry can be
used to identify patient who are likely to beneﬁt from therapy [7].
Such analyses should deﬁnitely take into account of medication
adherence, given their potential impact.
Conclusion
The results of this analysis show that nonadherence with
osteoporosis medications signiﬁcantly reduces the clinical and
economic outcomes of osteoporosis screening strategies. All
aspects of medication adherence (i.e., compliance, persistence
and primary adherence) should therefore be reported and
included in pharmacoeconomic analyses, and especially in the
presence of upfront cost of case ﬁnding (such as screening cost).
Source of ﬁnancial support: This study was performed as part of the PhD
of Mickaël Hiligsmann. No sources of funding were used to assist in the
preparation of this manuscript. The model development and validation
was previously supported by an ESCEO-Amgen Fellowship grant received
at the 6th European Congress on Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (Vienna 2006).
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